胰腺癌中针对KRAS的研究
Targeting KRAS in Pancreatic Cancer.
作者信息
Cowzer Darren, Zameer Mohammed, Conroy Michael, Kolch Walter, Duffy Austin G
机构信息
Department of Medical Oncology, Mater Misericordiae University Hospital, D07 R2WY Dublin, Ireland.
Systems Biology Ireland, School of Medicine, University College Dublin, Belfield, D04 E1W1 Dublin, Ireland.
出版信息
J Pers Med. 2022 Nov 8;12(11):1870. doi: 10.3390/jpm12111870.
Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock. Here, we review these innovations in therapies that target RAS signaling in pancreatic cancer from a clinical point of view. A number of promising approaches are currently in clinical trials or in clinical development. We focus on small-molecule drugs but also discuss immunotherapies and tumor vaccines.
胰腺癌主要由KRAS癌基因的突变驱动。虽然这种癌症表现出显著的治疗抗性，但抑制突变型KRAS、KRAS激活剂和效应器的新方法有望打破这种治疗僵局。在此，我们从临床角度综述针对胰腺癌中RAS信号传导的这些治疗创新。目前有一些有前景的方法正在进行临床试验或处于临床开发阶段。我们重点关注小分子药物，但也会讨论免疫疗法和肿瘤疫苗。
Zotero 插件